Rapid diagnostics High interest in rapid, lab-quality COVID-19 tests suitable for point-of-care use; potential to expand to other infectious diseases using their PCR-equivalent platform, offering a differentiator from slower standard PCR and antigen tests.

EV/ EUA readiness Product has FDA EUA authorization for emergency use in laboratories, indicating a favorable adoption curve with health systems that require authorized diagnostics; key lever for hospital systems and clinics seeking expedited solutions while regulatory processes proceed.

Small team agility Small workforce (2-10 employees) combined with niche product focus suggests a flexible, relationship-driven sales approach; potential need for channel partnerships or contract manufacturers to scale distribution and service support.

Leadership hires Recent addition of a VP of Sales & Marketing signals a push to scale commercialization; opportunity to engage early through aligned value messaging, case studies, and targeted outreach to procurement and clinical decision-makers.

Funding & momentum Current revenue range and modest funding indicate growth potential but likely needs strategic partnerships and outside capital to scale; ideal sales targets include mid-sized clinics, urgent-care networks, and regional laboratories seeking fast, accurate testing with predictable costs.